New Delhi: AIIMS Delhi will start human trials of Covaxin — country’s first indigenous COVID-19 vaccine — next week with 100 healthy volunteers in the age group of 18-55 years.
For a period of 150 days the volunteers will be kept under observation. The vaccine has been developed by Bharat Biotech collaborating with Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).
“We will begin human trials of India’s first indigenous vaccine, Covaxin, on 100 healthy volunteers aged between 18 and 55 years. We will ensure that none of the volunteers have any comorbidities. AIIMS will conduct trials on 100 volunteers out of a total of 375 persons,” Professor of Community Medicine and Principal Investigator of COVID-19 vaccine trial, Sanjay Rai was quoted as saying by news agency IANS.
